Celcuity stock (NASDAQ: CELC), a clinical-stage biotechnology company, experienced an extraordinary 3x surge in a single trading session, with shares rocketing from approximately $14 to a peak of $46 ...
Celcuity Inc. (NASDAQ:CELC) is among the 20 Best Performing Stocks in 2025. On December 12, 2025, TheFly reported that Wells Fargo started covering Celcuity Inc. (NASDAQ:CELC) with a $126 price target ...
Celcuity (CELC) is making strides with its lead therapeutic candidate, Gedatolisib, currently in Phase 3 clinical trials. It shows promising potential as a first-line treatment for HR+/HER2- advanced ...
Celcuity surges to a $2B valuation on strong phase 3 data for gedatolisib in hormone-positive breast cancer, affirming commercial potential. Gedatolisib shows significant progression-free survival ...
Celcuity, Inc. (CELC) closed the last trading session at $15.23, gaining 1.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall ...
CELC is trading at record highs today after the company's big breakthrough Biotech stock Celcuity Inc (NASDAQ:CELC) is skyrocketing today, up 221% at $43.76 at last glance, after upbeat phase 3 trial ...
We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. Celcuity Inc. is one of them. Celcuity Inc. (NASDAQ:CELC) is a clinical-stage biotechnology company developing ...
Celcuity Inc. retains a 'Buy' rating as gedatolisib advances toward a likely 2026 FDA approval and commercial launch. VIKTORIA-1 phase 3 data show gedatolisib delivers superior progression-free ...
On December 12, 2025, TheFly reported that Wells Fargo started covering Celcuity Inc. (NASDAQ:CELC) with a $126 price target and an Overweight rating. According to the firm, Phase 1 data and results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results